Description: Medlab Clinical Limited is engaged in the sale of nutraceutical products and pharmaceutical research. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. Its Manuka-C is scientifically formulated to support optimal immune system function and includes evidence-based ingredients containing a blend of over three ascorbates combined with glutathione and Manuka honey powder. Its NOS NITRIC OXIDE SUPPORT is a pre-exercise sports food containing a selection of evidence-based ingredients combined to support and optimize exercise performance. Its Saccharomyces cerevisiae ssp. boulardii (SB) 5B is a probiotic yeast that helps to maintain gastrointestinal function and integrity by supporting a healthy gut microbial profile; by increasing the production of secretory Immunoglobulin A (sIgA), short-chain fatty acids (SCFAs) and helping to promote the activity of brush border disaccharide enzymes. It also offers Mg Optima and BioClean EPA:DHA + CoQ10.
Home Page: www.medlab.co
MDC Technical Analysis
Building A
Botany,
NSW
2019
Australia
Phone:
61 2 8188 0311
Officers
| Name | Title |
|---|---|
| Dr. Sean Michael Hall | MD, CEO & Director |
| Mr. Kerem Kaya | CFO, COO & Company Sec. |
| Dr. David A. Rutolo (USA), J.D., Ph.D. | Director of Science |
| Mr. Ian Curtinsmith | Chief Information Officer |
| Mr. Tony Potter | Head of Pharmaceuticals |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0628 |
| Price-to-Sales TTM: | 10.85 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |